Lumoxiti

Active Ingredient(s): Moxetumomab Pasudotox-tdfk
FDA Approved: * September 13, 2018
Pharm Company: * ASTRAZENECA AB
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lumoxiti Overview

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.[2][3][4] Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL.[4] The drug consist...

Read more Lumoxiti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Moxetumomab_pasudotox

Recent Lumoxiti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lumoxiti: (1 result)

Sorted by National Drug Code

• 0310-4700 Lumoxiti 1 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Moxetumomab Pasudotox-tdfk or a similar ingredient: (1 result)

• MOXETUMOMAB PASUDOTOX